MedTrace Logo

Re-usable Respimat® Soft MistTM Inhaler Study

NCT04011735 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Respimat

Soft Mist Inhaler product

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2020-02-13
Completion
2020-02-13
FDA Drug
Yes

Countries

  • Belgium
  • Denmark
  • Finland
  • Germany
  • Netherlands
  • Norway

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04011735 on ClinicalTrials.gov